Vaccine and Immunisation Research Group, Doherty Institute, University of Melbourne
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nolan, Terry M
NCT05116241: Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children

Completed
2
367
Europe, RoW
BPZE1 pertussis vaccine and placebo, BPZE1 pertussis vaccine and Boostrix, Placebo and Boostrix
ILiAD Biotechnologies
Bordetella Pertussis, Whooping Cough
05/24
05/24
NCT05272605: Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults

Completed
1
76
RoW
Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59), SARS-CoV-2 beta variant RBD mRNA vaccine, Normal Saline
University of Melbourne, Southern Star Research Pty Ltd.
SARS-CoV-2
04/23
04/23
Shiels, Lani
NCT05272605: Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults

Completed
1
76
RoW
Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59), SARS-CoV-2 beta variant RBD mRNA vaccine, Normal Saline
University of Melbourne, Southern Star Research Pty Ltd.
SARS-CoV-2
04/23
04/23

Download Options